0001610618-24-000062.txt : 20240430 0001610618-24-000062.hdr.sgml : 20240430 20240430160755 ACCESSION NUMBER: 0001610618-24-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240426 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tadvalkar Laura CENTRAL INDEX KEY: 0002020464 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 24897195 MAIL ADDRESS: STREET 1: CIDARA THERAPEUTICS, INC. STREET 2: 6310 NANCY RIDGE DRIVE, SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4 1 wk-form4_1714507663.xml FORM 4 X0508 4 2024-04-26 0 0001610618 Cidara Therapeutics, Inc. CDTX 0002020464 Tadvalkar Laura 6310 NANCY RIDGE DRIVE STE 101 SAN DIEGO CA 92121 1 0 0 0 0 Stock Option (right to buy) 12.63 2024-04-26 4 A 0 4250 0 A 2034-04-25 Common Stock 4250 4250 D 1/3rd of the total number of shares subject to the award shall vest on April 26, 2025 and the remaining 2/3rds of the shares will vest in equal monthly installments over a two year period such that the option is fully vested on April 26, 2027. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Shane Ward, Attorney-in-Fact 2024-04-30